Bridgebio Pharma says it will seek U.S. approval of BBP-418 for LGMD2i after Phase 3 trial data showed a range of benefits ...

H.C. Wainwright raised the firm’s price target on BridgeBio (BBIO) to $80 from $70 and keeps a Buy rating on the shares. The firm now includes ...

We recently published 10 Big Names Crushing Wall Street. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the top-performing ...

The $12.5 billion acquisition of Avidity Biosciences Inc. by Novartis AG strengthens the company’s neuroscience pipeline and marks the second biggest deal that’s been announced this year. San ...

BridgeBio Pharma is a biotechnology company focused on bridging the gap between genetic research and unmet patient needs. Its pipeline targets Mendelian disorders, precision oncology, and gene therapy ...

BridgeBio Pharma ( ($BBIO) ) has shared an announcement. On October 27, 2025, BridgeBio Pharma announced positive results from its Phase 3 FORTIFY ...

BridgeBio Pharma shares surge on positive BBP-418 trial results for limb-girdle muscular dystrophy. Read more here.

Shares of BridgeBio Pharma rose more than 15% to $62.52 in early trading, after the company reported positive top-line ...

New interim data from a Phase III trial puts the company on track to file for FDA approval next year in an indication that ...

Investing.com -- BridgeBio Pharma (NASDAQ:BBIO) stock rose 15% after reporting positive Phase 3 results for its small molecule BBP-418 in the treatment of limb-girdle muscular dystrophy type 2I/R9 ...

BridgeBio Pharma said on Monday its experimental drug for a rare muscle disorder, which currently has no approved treatments, showed improvements in motor and lung function in a late-stage trial, ...

Shares of BridgeBio Pharma rose after the company reported positive data in the phase three study of its treatment of limb-girdle muscular dystrophy. The stock rose 10% to $59.74 in premarket trading ...